Photobiomodulation/Red Light Therapy research June 1st 2026
Share
Quick Answer: This week's standout paper is a randomised controlled trial showing that home-based 810nm transcranial photobiomodulation improved global cognition, episodic memory, and brain network connectivity in people with mild cognitive impairment - a prodromal stage of Alzheimer's disease. Separately, an open-label pilot found meaningful reductions in treatment-resistant depression using the same wavelength in a wearable LED helmet. And a mechanistic study in Advanced Science showed definitively that wavelength determines whether light drives inflammation or suppresses it - 850nm pushes immune cells toward healing, 625nm does the opposite.
Imagine your brain is like a phone battery that won't charge properly. You plug it in, you wait, and it just sits there at 12%. That's what early cognitive decline feels like for a lot of people. And that's what makes this week's papers worth your time.
The photobiomodulation (fotobiomodulasjon) research alert this week, covering papers published between 21 May and 4 June 2026, landed with some genuinely interesting clinical findings. Not all of them are ready to act on. But a few are the kind of thing you should know about, especially if you or someone close to you is dealing with cognitive changes, treatment-resistant depression, chronic back pain, or visual health.
I've been selling and using red light therapy (rødlysterapi) devices in Norway since 2018. I read these alerts every week. This week actually gave me something to write about. Let me walk you through it.
What Is Photobiomodulation? (Short version)
Red and near-infrared light (nærinfrarødt lys) in the 600nm to 1100nm range is absorbed by cytochrome c oxidase in the mitochondria. That absorption triggers increased ATP production, reduced oxidative stress, nitric oxide modulation, and downstream anti-inflammatory effects. The mechanism is well established. Whether it translates into clinical benefit for the condition you care about is what the research below is working through.
Can Red Light Therapy Help With Early Alzheimer's?
This is the most important paper in this week's alert. I want to be precise, because this is a sensitive area.
A single-blind, randomised, sham-controlled pilot trial published in the Journal of Alzheimer's Disease on 3 June 2026 (PMID 42231857) enrolled 20 adults over 50 with mild cognitive impairment (MCI) - the stage that often precedes Alzheimer's and related dementias. Ten received active treatment, ten received sham devices. The active device delivered pulsed 810nm near-infrared light for 20 minutes per session, six days a week, for six weeks, at home. It targeted the brain's default mode network (DMN) and olfactory bulb.
The results are striking for a pilot study: global cognition as measured by the Mini-Mental State Examination improved significantly in the active group versus sham (p=0.03, d=1.05). Episodic memory specifically improved (p=0.02, d=1.09). DMN functional connectivity increased (p=0.014). The lactate-to-pyruvate ratio dropped (p=0.007), which is a metabolic signal pointing toward improved mitochondrial efficiency. Plasma IL-6, a key inflammatory marker, also declined (p=0.02).
The effect sizes here (d=1.05 and d=1.09) are large for a pilot study. That's unusual and worth paying attention to. The metabolic and network-level findings are particularly meaningful because they suggest the mechanism is actually working - this isn't just a placebo effect.
Honest caveats: 20 participants is small. Single-blind rather than double-blind adds some risk of bias. The authors themselves frame this as preliminary. But the breadth of outcomes - cognitive, metabolic, neuroimaging, inflammatory - all moving in the same direction adds credibility you don't always see. Larger multicenter trials are now warranted and will likely happen.
For targeted 810nm near-infrared application, the 810nm therapy torch delivers the exact wavelength used in this research at verified output, useful when you need precision over a specific area rather than whole-body exposure.
(Rashidi-Ranjbar et al., Journal of Alzheimer's Disease, Read the study)
Transcranial PBM for Treatment-Resistant Depression: A Real Signal
Published on 2 June 2026 in Photobiomodulation, Photomedicine and Laser Surgery (PMID 42231103), this open-label pilot enrolled 29 adults with treatment-resistant depression (TRD) - meaning they had already failed at least two adequate antidepressant trials. They received a whole-brain transcranial PBM protocol using an 810nm LED helmet delivering 12.8W, 20 minutes per session, three times weekly for four weeks.
MADRS depression scores dropped from 35.5 at baseline to 22.9 post-treatment, a mean reduction of 12.5 points (p less than 0.001). Clinical response, defined as at least 50% score reduction, was achieved in 40.9% of per-protocol participants. Remission in 9.1%. The most common side effect was headache, reported by 50% of participants - mild to moderate in all cases. No serious adverse events.
This is open-label, no sham control, which is the study design's key limitation. You can't rule out placebo effect in a depression study without a proper sham arm. But 40.9% clinical response in a population that has already failed multiple treatments is a number that deserves attention. These are not easy patients to treat.
The fact that both this study and the MCI paper above use 810nm and target overlapping brain networks is not a coincidence. This wavelength has a specific affinity for cytochrome c oxidase and tissue penetration characteristics that make it the leading candidate for transcranial applications. The 810nm therapy torch delivers this wavelength at verified output for those looking at targeted near-infrared application.
(Monteiro et al., Photobiomodulation Photomedicine and Laser Surgery, Read the study)
Wavelength Determines Whether Light Heals or Inflames
This paper from Advanced Science (PMID 42227978, published 2 June 2026) is a mechanistic study, not a clinical trial, but it's probably the most scientifically important paper in this week's alert because it provides a clear framework for something the field has been arguing about for years.
The question: does wavelength really matter for whether PBM reduces or promotes inflammation? Yes. Definitively yes.
The researchers showed in both cell culture and in vivo wound healing models that 850nm light enhances fatty acid oxidation and drives macrophages toward an anti-inflammatory M2 state, accelerating tissue repair. By contrast, 625nm light increases glycolytic flux, drives macrophages toward a pro-inflammatory M1 state, and actually delays healing.
The mechanism they identified is mitochondrial dynamics: 850nm promotes mitochondrial fusion, which supports the oxidative metabolism of M2 macrophages. 625nm promotes fission, which supports the glycolytic metabolism of M1 macrophages. When they reversed these metabolic conditions experimentally, they reversed the polarisation outcomes - which is the kind of causality proof that strengthens mechanistic claims considerably.
What does this mean for you as someone using a home panel? It means the wavelength mix on your device genuinely matters. Devices using near-infrared wavelengths in the 800-900nm range for betennelsesdempende (anti-inflammatory) applications are doing something that lower-wavelength red light in the 620-630nm range may actually counteract. Not all red is the same. The devices I sell have been spectrometer-tested for exactly this reason. Before buying anything, ask for measured output data.
(Shi et al., Advanced Science, Read the study)
Back Pain Relief: A Real Randomised Controlled Trial
About 80% of people will experience significant back pain at some point. For us in Norway, where winters involve cold, sedentary indoor periods, lower back pain is something I hear about constantly. This week's alert included a longitudinal, randomised, placebo-controlled clinical trial published in the Journal of Biophotonics (PMID 42206653, 28 May 2026) that looked directly at this.
Patients with low back pain were randomised into five groups: laser combined with vacuum therapy, laser with roller, laser with ultrasound, laser alone, and placebo laser. All treatments covered the posterior trunk for 20 minutes, once weekly, for seven sessions.
The active groups showed pain reduction, increased isometric strength, improved flexibility, and improved mobility - with the combined therapy groups (especially laser with mechanical systems) showing the strongest results. Quality of life measures also improved.
Seven sessions is long enough to represent a meaningful treatment course, and the smertelindring (pain relief) findings across multiple modalities are consistent with the broader literature. What's particularly useful about this paper is that it examines PBM not in isolation but alongside other physiotherapy approaches. In practice that's how it tends to get used, and it's good to have evidence for the combined approach.
For large-area back treatment at home, the Large Body Max Panel gives you coverage across the full posterior trunk - the kind of surface area that actually corresponds to what was treated in this trial.
(Santos et al., Journal of Biophotonics, Read the study)
Red Light and the Myopic Eye: Retinal Function Improves
This study is interesting, and not just for the obvious reason of myopia management being a growing area in eye health.
Published in Vision (PMID 42201154, 27 May 2026), researchers at the University of Minho studied 36 subjects - myopes and non-myopes - using retinal electrophysiology before and after low-level red light therapy (RLRT) exposure. Three minutes of RLRT exposure significantly increased PERG N35-P50 amplitude in myopic subjects (baseline 0.88 microvolts vs post 1.40 microvolts, p=0.013). Non-myopes showed no significant change.
The finding has two layers of interest. First, the øyehelse (eye health) dimension: RLRT appears to acutely improve functional retinal signalling specifically in myopic eyes, which are known to have greater mitochondrial stress in the retinal cells. Second, the pattern fits the general PBM principle that compromised or stressed tissue responds more to photobiomodulation than healthy tissue - the myopic retina has more room to improve.
This is a short-term measurement study, not a clinical outcomes trial. We don't know yet whether these acute electrophysiological improvements translate into long-term structural benefits like reduced axial length progression. Prof. Glen Jeffery's work on red light and retinal mitochondria provides the theoretical underpinning here, and it's a growing area of research that I'll keep covering.
(Qasim et al., Vision, Read the study)
PBM and Sleep Apnea: An Insulin Resistance Connection
This one comes from mice rather than humans, so I'll keep it proportionate. But it's worth flagging because the connection it maps is clinically meaningful.
Published in Comprehensive Physiology (PMID 42216497, 30 May 2026), French researchers exposed mice to chronic intermittent hypoxia to mimic obstructive sleep apnea (OSA) - a condition affecting significant numbers of Norwegians and linked to metabolic disease. Some mice received PBM (630nm, 5 J/cm2, five days per week) alongside the hypoxia exposure.
PBM significantly improved systemic insulin sensitivity, prevented disruption of adipose tissue insulin signalling, and reduced hepatic oxidative stress in the hypoxic mice. In normoxic mice, PBM had no significant metabolic effect - again consistent with the pattern of greater response in compromised tissue.
OSA affects metabolic health in ways that most people don't connect. The oxidative stress and insulin resistance that accumulate from chronic sleep-disordered breathing are not trivial. This is early-stage animal research, but it opens a genuinely interesting direction for investigating PBM as a metabolic adjunct in people with OSA-related metabolic complications.
(Paradis et al., Comprehensive Physiology, Read the study)
Multiple Sclerosis: A Scoping Review of Mechanisms
A scoping review published in International Immunopharmacology (PMID 42208329, 28 May 2026) synthesised preclinical and clinical evidence on PBM mechanisms in multiple sclerosis. It's a review rather than new trial data, but it's a useful synthesis for anyone interested in neurological applications.
The findings: PBM enhances mitochondrial bioenergetics, exerts antioxidative effects, modulates neuroimmune-glial crosstalk, and supports neuroprotective cellular responses. These are the same downstream mechanisms that appear across many neurological PBM applications. The review frames these as a rational basis for clinical translation in MS management.
MS affects roughly 1 in 1000 Norwegians - higher than the global average - and current disease-modifying therapies address the immunological component but have limited impact on the mitochondrial dysfunction and neurodegeneration that accumulate over time. PBM's potential to target that dimension directly is what makes this area worth watching.
Evidence in human MS patients is still limited. The review acknowledges this and calls for clinical translation. This is a follow-the-research situation.
(Xie et al., International Immunopharmacology, Read the study)
The Honest Picture
This week's alert is actually better than average in terms of clinical relevance. The MCI/Alzheimer's RCT and the treatment-resistant depression pilot are the standout papers - not because they're definitive, but because they're properly designed preliminary evidence in areas where the need is enormous and current options are limited.
The wavelength paper from Advanced Science is scientifically significant regardless of clinical applications. It tells you mechanistically why wavelength selection matters. That knowledge should inform every device purchase decision and every clinical protocol going forward.
What remains true, and what I will keep saying: protocol matters, device quality matters, and consumer panels are not the same as research-grade devices. The studies above used verified, calibrated equipment. Before you buy anything on the basis of this research, ask for spectrometer-verified output data. If a seller cannot provide that, the answer is no.
The red light therapy panels and portable and specialist devices on this site have been tested. I know what they put out.
FAQ
What is photobiomodulation (fotobiomodulasjon)? It is the use of red and near-infrared light to trigger cellular responses, primarily through absorption by the mitochondrial enzyme cytochrome c oxidase. Red light therapy (rødlysterapi) is the consumer term for the same process. Same mechanism, different vocabulary.
Can transcranial photobiomodulation help with memory and cognition? A pilot RCT published this week in the Journal of Alzheimer's Disease found meaningful improvements in global cognition and episodic memory in people with mild cognitive impairment using home-based 810nm near-infrared PBM for six weeks. The effect sizes were large for a pilot study. It needs replication in larger trials but represents the strongest controlled evidence to date in this area.
Does wavelength matter when choosing a red light device? Yes, and a paper published this week in Advanced Science confirmed it mechanistically. 850nm near-infrared light drives anti-inflammatory immune responses and tissue repair. Lower wavelength red light around 625nm does the opposite, driving pro-inflammatory responses. This is not a minor detail - it should inform which device you buy.
Is red light therapy effective for back pain (smertelindring)? A randomised controlled trial published this week showed significant pain reduction, strength improvement, and mobility gains over seven sessions of laser PBM applied to the posterior trunk. Results were strongest when PBM was combined with physical therapy techniques. The evidence for low back pain is among the more consistent in the field.
Is PBM being researched for multiple sclerosis? A scoping review published this week confirmed that PBM has demonstrated relevant mechanistic effects in MS models, including mitochondrial support and neuroimmune modulation. Human clinical evidence remains limited. This is a watch-this-space area.
What is the difference between a panel and a targeted torch for home use? A panel like the Large Body Max treats large surface areas - full back, multiple muscle groups, whole-body coverage relevant to the back pain and metabolic research above. A targeted device like the 810nm torch delivers specific wavelength application to a precise location - relevant for the transcranial, cognitive, and retinal applications covered this week. Both are useful, but for different purposes.
Disclaimer: This post is for informational and educational purposes only. Nothing here constitutes medical advice. Photobiomodulation devices are not approved to diagnose, treat, or cure any medical condition. If you have a health condition, consult a qualified healthcare provider before starting any light therapy protocol.
[Meta description: Photobiomodulation June 2026: Alzheimer's RCT, treatment-resistant depression, back pain (smertelindring), wavelength science and myopia. This week's PubMed findings.]
Meta description character count: 158